Ionis Pharmaceuticals, Inc. - Common Stock (IONS)

As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as the pioneer of RNA interference (RNAi) technology, Alnylam has successfully transitioned from a research-heavy enterprise to a fully integrated, profitable commercial leader. With the recent expansion of [...]

UniFirst provides workplace uniforms and facility services via recurring contracts to a broad customer base in North America and beyond.

Autoliv develops advanced safety systems for global automakers, supplying airbags, seatbelts, and related technologies worldwide.

As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the Cambridge-based company has matured into a biopharmaceutical titan with a market capitalization exceeding $50 billion. Today, Alnylam is no longer just a "biotech story"; [...]

Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027.

Ionis' olezarsen cut triglycerides by up to 72% and reduced acute pancreatitis events by 85% in Phase 3 studies of severe hypertriglyceridemia.

The company remains confident in its other gene-editing product, which would treat a swelling disorder.

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam Therapeutics.

Ionis (IONS) Q3 2025 Earnings Call Transcript

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

IONIS Pharmaceuticals stock shows strong technical and fundamental momentum, meeting strict trend-following criteria with surging earnings and revenue growth.

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by the company's recent strategic guidance, which forecasts over $5 billion in potential annual peak sales from its robust pipeline of

The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs.